Latest From Biotech Now

Massachusetts Governor and Lawmakers Improve Patient Access

Deval-btn

Earlier this week Massachusetts Governor Deval Patrick signed the 2013 budget. Within that budget are two provisions that will ultimately benefit healthcare consumers within the Commonwealth. The first provision was a partial repeal of the Massachusetts gift ban law enacted two years ago. In the words of Governor Patrick, “This narrow change will afford healthcare providers some flexibility to be educated on new clinically relevant products and allow them to stay informed on advancements in Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

Senator John Kerry and the 2012 BIO International Convention

kerry-btn

One of our scheduled keynote speakers at the 2012 BIO International Convention in Boston was Senator John Kerry of Massachusetts. Unfortunately the Senator was unable to join us as planned when his duties kept him in Washington, DC for votes on important legislation. Senator Kerry has been a strong supporter of biomedical innovation. During the health care reform debate, Senator Kerry strongly supported and fought for a 12-year data exclusivity period for innovative biomedicines and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

FDA Safety and Innovation Act: A Step Forward for Patients With Rare Diseases

Peter L. Saltonstall

By Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD) The Food and Drug Administration Safety and Innovation Act (FDASIA) includes the most groundbreaking measures for rare disease patients and their families since the Orphan Drug Act of 1983.  And, just as the rare disease patient community—with NORD as its unifying voice—played a major role in the Orphan Drug Act, NORD and rare disease patients have taken a leadership role in developing Read More >

Health  |  13 Comments  |  Email This Post
Tags: , , , , , , , , ,

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

Index-Perfomance-June-2012-thumb

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD: 2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M.  The company was formed just two years ago and has aggressively in-licensed cancer treatments from Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

See for Yourself: New BIO Book Showcases Visible Progress in Industrial Biotech

biofuel-plant-btn

BIO recently introduced a picture book of biorefineries across the United States, “Visible Progress in Commercialization of Advanced Biofuels, Biobased Products and Renewable Chemicals”, which showcases commercial, demonstration and even new pilot facilities. Some of these facilities have been in operation for as long as a decade while others are new plants under construction. They include the first commercial-scale cellulosic biofuel production biorefineries and facilities for ongoing research and development of industrial biotech products. Biorefineries Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , ,